^
Association details:
| Biomarker: | SDC1 positive |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | MA9060 (Autophagy inhibitor, ULK3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ULK3-mediated autophagy is a tractable therapeutic target for the treatment of multiple myeloma.
Published date:
09/10/2023
Excerpt:
Ex vivo, we demonstrated the efficacy of MA9060 for the treatment of CD138+ MM derived from newly diagnosed and refractory patients both as a single agent and in combination with standard of care therapies such as the proteasome inhibitor, carfilzomib.
Secondary therapy:
carfilzomib
